@inbook{3422d7a989ce4b6ab85cb9fa1f1d4370,
title = "Substance P-saporin for the treatment of intractable pain",
abstract = "Pain is a worldwide chronic health issue, and additional therapies are needed for the management of severe pain. Substance P-Saporin (SP-SAP) covalently links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing.We review the history of SP-SAP and related NK1-receptor targeted toxins. We review animal data on the safety and efficacy of SP-SAP for the treatment of pain in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor. Finally, we discuss possible mechanisms of action of SP-SAP.",
keywords = "Allodynia, Hyperalgesia, NK1, Pain, SP-SAP, Substance P",
author = "Hugh Nymeyer and Lappi, {Douglas A.} and Denise Higgins and Noe, {Carl E.} and Frankel, {Arthur E.}",
note = "Publisher Copyright: {\textcopyright} Springer International Publishing AG 2017.",
year = "2017",
doi = "10.1007/978-3-319-46877-8_6",
language = "English (US)",
series = "Milestones in Drug Therapy",
publisher = "Springer Basel",
pages = "107--130",
booktitle = "Milestones in Drug Therapy",
}